These fast-growing companies have new personnel announcements to share. Photos courtesy

Three Houston startups have new hires they're excited about.

From new board members to c-level execs, here's who's moving and shaking in Houston innovation.

GoExpedi names senior vice president of sales

Michael Hanes will focus on sales at fast-growing GoExpedi. Photo courtesy of GoExpedi

E-commerce and supply chain company, GoExpedi, which is focused on transforming procurement for industrial and energy maintenance, repair and operations, has announced named a new executive.

Michael Hanes has been onboarded as senior vice president of sales. Hanes has over 20 years of experience in startups and emerging technologies. Most recently, Hanes worked at Heart Rhythm Society as its director of corporate relations.

"There are very few leaders that have the same level of sales experience and the diverse industry background as Michael. He is an outstanding addition to our team, as he's already started to build fruitful relationships with customers and partners, who are embracing change through the adoption of our interactive intelligence platforms," says Tim Neal, GoExpedi CEO, in a news release.

"Michael has also begun establishing a strong rapport with all of our sales leaders across the country, helping to further sharpen our processes and accelerate the growth of our already robust sales pipeline," Neal continues. "He will be instrumental for the expansion of our customer base and overall success."

Last fall, GoExpedi raised $25 million in a series C investment round in order to keep up with growth and demand.

"I am thrilled to join GoExpedi. What Tim and his team have built in just a few short years is nothing short of remarkable," says Hanes in the release. "Driving the sale of a truly innovative technology -- with the support of a deeply talented team of sales professionals -- is an amazing position to be in.

"I look forward to introducing fresh perspectives and bringing energy to further enhance our sales processes and market presence and accelerate the company's already fast-paced growth trajectory."

The Postage announces new board of directors member

Former startup CFO and venture capital adviser is joining a Houston tech company's board. Photo via liveoakvp.com

Lynn Atchison has joined the board of directors for Houston tech company The Postage, a full-service digital platform and mobile app for afterlife planning.

Based in Austin, Atchison most recently served as CFO at Khoros (née Spredfast) and also previously worked at HomeAway Inc. as CFO as well. She currently serves on other tech boards, such as Absolute Software, Bumble, Q2 Technologies and Convey, as well as being an advisory partner at LiveOak Venture Partners.

"As evidenced by her impressive experience, Lynn thrives when working with transformational and fast-growing companies, making The Postage a perfect fit," says Emily Cisek, CEO and co-founder of The Postage. "She has scaled operations, driven growth and improved profitability for companies in all lifecycle stages. We are absolutely thrilled to welcome Lynn to The Postage team."

The Postage launched last fall as a way to help simplify afterlife planning. Cisek was inspired to create her tech solution after she lost three family members back to back. This month, the company announced its new app.

During her time at HomeAway, Atchison oversaw more than 20 acquisitions and global expansions before the company went public in 2011 before being acquired by Expedia in 2015 for $3.9 billion.

"Throughout my career, I've worked with companies that redefined and established markets, ultimately becoming leaders in their respective industries, which is what I hope to do at The Postage," said Atchison. "Addressing the challenges associated with end-of-life planning is an exciting opportunity that I can personally relate to. I recently experienced a loss in my family, and I know there is something special about this idea. The Postage creates security of all users by ensuring that their families are taken care of after they pass."

Innowatts appoints new c-level exec

Energy software expert Jeff Wright has joined the globally expanding Innowatts. Photo courtesy of Innowatts

As Houston-based Innowatts continues its global expansion — most recently opening its European Union headquarters in Cork, Ireland, the energy software-as-a-service company has named a new member to its C suite.

Jeff Wright has been named the chief revenue officer of Innowatts. to drive continued expansion in the U.S. and also accelerate its growth globally. Wright was previously the global vice president of GE Digital's Grid Solutions business unit. During his tenure, GE's market position climbed from the No. 5 to No. 1 for its energy control room related software, according to a news release.

"Jeff's career can be summarized as 'Energy Meets Technology,'" says Innowatts CEO Siddhartha Sachdeva in the release. "As Innowatts business and global reach expands, we are grateful to have Jeff joining the company. He is a true energy tech leader who has second-to-none domain expertise across a diverse set of utility functions and operating units."

Wright will lead all aspects of the company's go-to-market initiatives and oversee global sales efforts and marketing channels.

"My passion to help companies disrupt and transform the utility industry aligns squarely with Innowatts' mission," says Wright in the release. "Innowatts is transforming the way energy providers will leverage data and AI to operate. Playing a pivotal role in the growth of the company coupled with driving the resilient and sustainable energy solutions of the future is a career opportunity that I am excited and passionate about. I'm truly delighted to be part of the Innowatts leadership team."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.